Status: Not yet recruiting
HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB
The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacodynamics (PD) of multiple doses of ALN-6400 in adult and adolescent patients with VWD and HMB
Participants needed: 24
Trial details
Phase: Phase 2Age: 16-45Biological sex: FemaleType: InterventionalSponsor: Alnylam PharmaceuticalsUpdated: Jun 15, 2026Locations: 1
Eligibility criteria
Is an adolescent or adult patient with a diagnosis of VWD (including Type 1, Typ...
Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater t... [+6]